Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 7 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 12010979

    Non-human animals comprising a humanized TTR locus and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  2. US 12012444

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  3. US 12012445

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  4. US 11999777

    Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  5. US 12000839

    Methods for characterizing disulfide bonds

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  6. US 11999799

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  7. US 11986511

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted May 21, 2024 · Expires May 16, 2044

    granted
  8. US 11975045

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  9. US 11965161

    Methods and compositions for sensitization of tumor cells to immune therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  10. US 11964016

    Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  11. US 11965020

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  12. US 11958910

    Bispecific antigen binding molecules that bind HER2, and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  13. US 11957687

    Modulators of HSD17B13 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  14. US 11958894

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  15. US 11957704

    Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  16. US 11951216

    Polymer protein microparticles

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  17. US 11944666

    Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted
  18. US 11945872

    Anti-ACVR1 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted
  19. US 11932692

    Methods of treating cancer pain by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  20. US 11926668

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  21. US 11926670

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  22. US 11926661

    Human antibodies to artemin and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  23. US 11919972

    Peptide libraries with non-canonical amino acids

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  24. US 11919965

    Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted